BV100

DRUG6 trials

Sponsors

BioVersys SAS, BioVersys AG

Conditions

Bacterial InfectionsHealthy ParticipantsHealthy SubjectsHealthy VolunteersRenal Impairment

Phase 1

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Male Subjects

CompletedNCT04636983

BioVersys SASHealthy Subjects

Start: 2020-11-09End: 2022-01-20Updated: 2022-02-08

Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment

CompletedNCT05086107

BioVersys AGRenal Impairment

Start: 2021-10-08End: 2023-01-16Updated: 2023-01-18

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male Subjects

CompletedNCT05087069

BioVersys SASHealthy Volunteers

Start: 2021-10-08End: 2023-01-12Updated: 2023-01-17

A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants

CompletedNCT05537090

BioVersys AGHealthy Volunteers

Start: 2022-09-01End: 2023-09-30Updated: 2023-11-21

A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment

CompletedNCT05537142

BioVersys AGHealthy Participants

Start: 2022-09-02End: 2024-10-30Updated: 2025-01-14

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

CompletedNCT05684705

BioVersys AGBacterial Infections

Start: 2023-09-01End: 2024-12-30Updated: 2025-01-14

Related Papers

Single-ascending and multiple-ascending dose study of the pharmacokinetics, safety, and tolerability of BV100 (rifabutin for infusion) in healthy volunteers.

2026-03-02